Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Drug Discovery
AbbVie and Gilgamesh Pharmaceuticals partner for psychiatric drugs
by Sarah Braner
May 16, 2024
| A version of this story appeared in
Volume 102, Issue 15
AbbVie and Gilgamesh Pharmaceuticals have entered an option-to-license agreement for new drugs for psychiatric disorders. The agreement centers on discovering novel drugs that enhance neuroplasticity, like psychedelics do, while avoiding unwanted psychoactive effects such as hallucinations. AbbVie says second-generation “neuroplastogens” hold the potential to treat mood and anxiety disorders. AbbVie will pay Gilgamesh $65 million up front.
Chemical & Engineering News
ISSN 0009-2347
Copyright © 2024 American Chemical Society
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter